Skip to content

Clinical therapeutic effect of high flow oxygen inhalation (hfnc) combined with respiratory rehabilitation on patients with acute attack of COPD: a multicenter prospective randomized controlled clinical study

Clinical therapeutic effect of high flow oxygen inhalation (hfnc) combined with respiratory rehabilitation on patients with acute attack of COPD: a multicenter prospective randomized controlled clinical study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030129
Enrollment
Unknown
Registered
2020-02-24
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Group 2:HFNC and pulmonary rehabilitation
Group 3:pulmonary rehabilitation
Group 4:conventional therapy

Sponsors

Zhongshan Hospital Affiliated Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with acute exacerbation of COPD are also diagnosed according to the guideline, classification and stage; 2. Aged 40 to 80 years; 3. Received standard bronchodilator drugs; 4. Non-participation in other lung rehabilitation studies or other influential studies.

Exclusion criteria

Exclusion criteria: 1. Patients with chronic cough caused by tuberculosis, fungus, tumor, irritant gas, allergy, etc; 2. Patients with other respiratory diseases that can cause asthma or dyspnea; 3. Pregnant or lactating women, allergic to this drug; 4. patients with severe primary diseases such as cardiovascular, liver, kidney and hematopoietic system, diabetes and mental illness; 5. Those with severe center of gravity dysfunction; 6. Patients receiving medication for other diseases; 7. Patients with observational factors affecting curative effect; 8. Failure to follow prescribed medication, inability to determine efficacy or incomplete information, etc. Those who influence efficacy or safety judgment.

Design outcomes

Primary

MeasureTime frame
pulmonary function;CAT;mMRC;SGRQ;6MWT;SAS;SDS;clinical symptoms;

Countries

China

Contacts

Public ContactLi Shanqun

Zhongshan Hospital Affiliated to Fudan University

lsq18616880856@163.com+86 18616880856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026